Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : $162.0 million
Deal Type : Series D Financing
Bayer and RTW Investments Lead Series D in Chinese Biotech Ji Xing Pharmaceuticals
Details :
Product Name : CK-3773274
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 01, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : $162.0 million
Deal Type : Series D Financing